Neurological consequences caused by SARS-CoV-2
DOI:
https://doi.org/10.33448/rsd-v10i14.22073Keywords:
COVID-19; Nervous System Diseases; SARS-CoV-2.Abstract
The crisis of the new coronavirus has several long-term consequences for society as hundreds of countries live in a regime of physical distance and social isolation. Studies also prove the existence of neurological symptoms in patients with COVID-19, such as headache, dizziness and impaired consciousness. This is an integrative literature review, carried out according to the steps: elaboration of the research question, bibliographic survey, data evaluation, data analysis and presentation of results. The databases used were Medical Literature Analysisand Retrieval System Online and Science Direct. The search in the databases resulted in 1,768 publications, which were selected by the eligibility criteria, resulting in a final sample of 12 articles. Different neurological damages associated with COVID-19 infection were identified, which allow discussions on how these consequences can happen and what factors are involved. It is considered that serious damage is more present in the population of risk groups, the elderly and people with comorbidities. The studies associated with the consequences of SARS-CoV-2 are very much directed to care and attention to the respiratory system, which promotes a smaller number of studies directed to the neurological system, however, there is evidence, case series and studies that represent neurological damage by the new coronavirus. Thus, the neurological manifestations found in patients with COVID-19 need assistance to assist providers in the treatment, management and recognition of potentially fatal neurological complications.
References
Aghagoli, G. et al. (2021). Neurological involvement in COVID-19 and potential mechanisms: a review. Neurocriticalcare. 34(3), 1062-71. 10.1007/S12028-020-01049-4.
Beghi, et al. (2020). COVID-19 infection and neurological complications: presente findings and future predictions. Neuroepidemiology. 54(4), 1-6. 10.1159/000508991.
Carod-Artal, F. J. et al. (2020). Neurological complications of coronavirus and COVID-19. Revista de neurologia. 70(9), 311-22. 10.33588/rn.7009.2020179.
COUTO, M. T., Barbieri, C. L. A. & Matos, C. C. S. A. (2021). Considerações sobre o impacto da covid-19 na relação indivíduo-sociedade: da hesitação vacinal ao clamor por uma vacina. Saúde e Sociedade. 30. 10.1590/S0104-12902021200450.
Das, G., Mukherjee, N. & Ghosh, S. (2020). Neurological insights of COVID-19 pandemic. ACS chemical euroscience. 11(9), 1206-09. https://doi.org/10.1021/acschemneuro.0c00201.
Desforges, M. et al. (2020). Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 12(1), 14. https://doi.org/10.3390/v12010014.
Franke, C. et al. (2021). High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain, behavior, andimmunity. 93, 415-9. https://doi.org/0.1016/j.bbi.2020.12.022.
Gasmi, A. et al. (2021). Neurological involvements of SARS-CoV2 infection. Molecular neurobiology. 58(3), 944-49. https://doi.org/10.1007/s12035-020-02070-6.
Harapan, B. N. & Yoo, H. J. (2021). Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). Journal of Neurology. 268(9), 1-13. 10.1007/s00415-021-10406-y.
Hay, M. et al. (2021). Serum neurofilament light is elevated in COVID-19 positive adults in the ICU and is associated with co-morbid cardiovascular disease, neurological complications, and acuity of illness. medRxiv. https://doi.org/10.1101/2021.04.28.21256277.
Helms, J. et al. (2020). Neurologic features in severe SARS-CoV-2 infection. New England Journal of Medicine. 382(23), 2268-70. 10.1056/NEJMc2008597.
Mahalakshmi, A. M. et al. (2021). Does COVID‐19 contribute to development of neurological disease? Immunity, inflammation and disease. 9(1), 48-58. 10.1002/iid3.387.
Miller, D. et al. (2020). Full genome viral sequences inform patterns of SARS-CoV-2 spread into and within Israel. Nature communications, 11(1), 1-10. 10.1038/s41467-020-19248-0.
Needham, E. J. et al. (2020). Neurological implications of COVID-19 infections. Neurocriticalcare. 32(3), 667-71. 10.1007/s12028-020-00978-4.
OPAS/OMS BRASIL. (2021). Folha informativa sobre COVID-19. https://www.paho.org/pt/covid19#datas-noticificacoes.
Qin, Y. et al. (2021). Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. The Journal of Clinical Investigation. 131(8). 10.1172/JCI147329.
Saif, L. J. (2020). Vaccines for COVID-19: perspectives, prospects, and challenges based on candidate SARS, MERS, and animal coronavirus vaccines. Euro Med J. 200324. 10.33590/emj/200324.
Tay, M. Z. et al. (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology. 20(6), 363-74. 10.1038/nature01096.
Toscano, G. et al. (2020). Guillain–Barré syndrome associated with SARS-CoV-2. New England Journal of Medicine, 382(26), 2574-76. 10.1056/NEJMc2009191.
Wang, F., Kream, R. M. & Stefano, G. B. (2020). Long-term respiratory and neurological sequelae of COVID-19. Medical science monitor: international medical journal of experimental and clinical research. 26. 10.12659/MSM.928996.
Whittaker, A., Anson, M., Harky, A. (2020). Neurological manifestations of COVID‐19: a systematic review and current update. Acta Neurologica Scandinavica. 142(1), 14-22. 10.1111/ane.13266.
Whittermore, R., Knafl, K. (2005). The integrative review: updated methodology. Journal of advanced nursing. 52(5), 546-53. 10.1111/j.1365-2648.2005.03621.x.
Ye, M., Ren, Y. & Lv, T. (2020). Encephalitis as a clinical manifestation of COVID-19. Brain, behavior, andimmunity. 88, 945. 10.1016/j.bbi.2020.04.017.
Zhang, A. et al. (2021). Epidemiology and evolution of Middle East respiratory syndrome coronavírus, 2012–2020. Infectious Diseases of Poverty. 10(1), 1-13. 10.1186/s40249-021-00853-0.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Maria Gabryelle da Silva Soares; Maria Letícia Cardoso da Silva Barbosa; Maria Eduarda Wanderley de Barros Silva; Kaliana Xavier Siqueira; Ana Regina da Silva Pereira ; Bianca Maria Mendes da Silva; Rodrigo Medeiros Gurgel de Faria; Arthu Línniker Lopes de Oliveira; Thalita Rafael do Nascimento; Isis Yohana Garcia Cipriano; Ednilma Barbosa Silva; Renata da Silva Ferreira; Larissa Lima Soares
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
